hyaluronoglucosaminidase has been researched along with paclitaxel in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 6 (46.15) | 2.80 |
| Authors | Studies |
|---|---|
| Ardizzoni, A; Bertelli, G; Cafferata, MA; Dini, D; Gozza, A; Rosso, R | 1 |
| Aldrich, C; Bahary, N; Braiteh, F; Bullock, AJ; Chondros, D; Harris, WP; Hendifar, AE; Hingorani, SR; Jiang, P; Khelifa, S; Oberstein, PE; Pu, J; Ritch, PS; Seery, TE; Sigal, DS; Wang-Gillam, A; Wu, W; Zalupski, MM; Zheng, L | 1 |
| Corrie, PG; Doherty, GJ; Tempero, M | 1 |
| Gourd, E | 1 |
| Cheng, H; Ding, Y; Djamila, A; Dong, Q; Han, Y; Tang, Z; Zhang, H; Zhou, J | 1 |
| Gao, H; He, X; Liu, R; Qin, L; Xiao, W; Xie, R; Yang, X; Yang, Z; Yu, W | 1 |
| Choi, HG; Kim, H; Kim, HK; Kim, SS; Lee, ES; Lee, WT; Oh, KT; Youn, YS | 1 |
| Bager, CL; Chondros, D; Karsdal, MA; Taverna, D; Wang, S; Willumsen, N | 1 |
| Blouw, B; Colombo, M; D'Incalci, M; Davoli, E; Frapolli, R; Fuso Nerini, I; Kang, DW; Meroni, M; Minoli, L; Morosi, L; Panini, N; Porcu, L; Ubezio, P; Zucchetti, M | 1 |
| Götte, M; Győrffy, B; Kiesel, L; Parnigoni, A; Passi, A; Riecks, J; Vigetti, D | 1 |
| Chen, M; Ge, X; Liu, J; Ma, Q; Tang, Y; Wen, Q; Zhang, L; Zhao, M; Zhu, L | 1 |
| Ajani, J; Al-Sakaff, N; Allen, S; Alsina Maqueda, M; Cha, E; Gan, X; Kim, KP; Ko, AH; Lacy, J; Lau, J; Lee, J; Lopez, CD; Lu, D; Macarulla, T; Manji, GA; O'Reilly, EM; Oh, DY; Rha, SY; Shemesh, CS; Siveke, JT | 1 |
5 trial(s) available for hyaluronoglucosaminidase and paclitaxel
| Article | Year |
|---|---|
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Enoxaparin; Female; Fibrinolytic Agents; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Thromboembolism; Time Factors | 2018 |
HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Tumor Microenvironment | 2018 |
PEGPH20 for metastatic pancreatic ductal adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Hyaluronoglucosaminidase; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; San Francisco; Survival Rate; Treatment Outcome | 2018 |
Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Extracellular Matrix; Humans; Hyaluronoglucosaminidase; Paclitaxel; Pancreatic Neoplasms | 2021 |
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Humans; Hyaluronoglucosaminidase; Paclitaxel; Pancreatic Neoplasms; Stomach Neoplasms | 2023 |
8 other study(ies) available for hyaluronoglucosaminidase and paclitaxel
| Article | Year |
|---|---|
Skin ulceration potential of paclitaxel in a mouse skin model in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Extravasation of Diagnostic and Therapeutic Materials; Humans; Hyaluronoglucosaminidase; Male; Mice; Paclitaxel; Skin Ulcer; Taxoids | 1997 |
PEGPH20 May Improve Standard-of-Care Therapy in Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Paclitaxel; Pancreatic Neoplasms | 2018 |
Tumor environment differentiated "nanodepot" programmed for site-specific drug shuttling and combinative therapy on metastatic cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Combined Modality Therapy; Drug Carriers; Female; Humans; Hyaluronoglucosaminidase; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Polyesters; Polyethyleneimine; Proteins; RNA Interference; RNA, Small Interfering; Tumor Microenvironment | 2018 |
Sequentially responsive biomimetic nanoparticles with optimal size in combination with checkpoint blockade for cascade synergetic treatment of breast cancer and lung metastasis.
Topics: Animals; B7-H1 Antigen; Biomimetic Materials; Breast Neoplasms; Cations; Cell Death; Cell Line, Tumor; Endocytosis; Female; Gold; Humans; Hyaluronoglucosaminidase; Immunotherapy; Lung Neoplasms; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Paclitaxel; Particle Size; Peptides; RAW 264.7 Cells; Reactive Oxygen Species; Tissue Distribution | 2019 |
Hyperthermal paclitaxel-bound albumin nanoparticles co-loaded with indocyanine green and hyaluronidase for treating pancreatic cancers.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Hyaluronoglucosaminidase; Indocyanine Green; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Photothermal Therapy | 2021 |
PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Female; Humans; Hyaluronoglucosaminidase; Mice; Neoplasms; Paclitaxel; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
The hyaluronan-related genes HAS2, HYAL1-4, PH20 and HYALP1 are associated with prognosis, cell viability and spheroid formation capacity in ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Cell Survival; Cisplatin; Female; Glucuronosyltransferase; Humans; Hyaluronan Synthases; Hyaluronic Acid; Hyaluronoglucosaminidase; Ovarian Neoplasms; Paclitaxel; Prognosis; RNA, Messenger; RNA, Small Interfering | 2022 |
Hyaluronidase responsive second near-infrared fluorescent nanocomplex for combined HER2 blockade and chemotherapy of HER2+ breast cancer.
Topics: Animals; Breast Neoplasms; Coloring Agents; Female; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2022 |